Literature DB >> 28560779

Efficacy and tolerability of initial high vs low doses of S-(-)-amlodipine in hypertension.

Qi Chen1, Qi-Fang Huang1, Yuan-Yuan Kang1, Shao-Kun Xu1, Chang-Yuan Liu1, Yan Li1, Ji-Guang Wang1.   

Abstract

In an 8-week randomized trial of patients with mild or moderate hypertension, the authors investigated the efficacy and tolerability of initial high (5.0 mg/d) vs low (2.5 mg/d) doses of S-(-)-amlodipine (equivalent to 5 and 10 mg of racemic amlodipine, respectively). In the S-(-)-amlodipine 2.5-mg group (n=263), 24-hour ambulatory systolic/diastolic blood pressure (±standard deviation) decreased from 131.5±15.0/82.1±10.7 mm Hg at baseline to 126.0±13.5/78.5±9.5 mm Hg at 8 weeks of follow-up by a least square mean (±standard error) change of 6.0±0.6/3.8±0.4 mm Hg. In the S-(-)-amlodipine 5-mg group (n=260), the corresponding changes were from 133.6±13.7/83.1±9.9 mm Hg to 125.0±12.0/78.2±8.9 mm Hg by 8.1±0.6/4.7±0.4 mm Hg, respectively. The between-group differences in changes in 24-hour systolic/diastolic blood pressure were 2.1/0.9 (P=.02/.17) mm Hg. Similar trends were observed for daytime and nighttime ambulatory and clinic blood pressure. The incidence rate was similar for all adverse events. An initial high dose of S-(-)-amlodipine improved ambulatory blood pressure control with similar tolerability as an initial low dose in hypertension. ©2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  S-(-)-amlodipine; ambulatory blood pressure; efficacy; initial dose; tolerability

Mesh:

Substances:

Year:  2017        PMID: 28560779      PMCID: PMC8031062          DOI: 10.1111/jch.13022

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  27 in total

Review 1.  Clinical usefulness of ambulatory blood pressure monitoring.

Authors:  Paolo Verdecchia; Fabio Angeli; Roberto Gattobigio
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

2.  Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension.

Authors:  Denis L Clement; Marc L De Buyzere; Dirk A De Bacquer; Peter W de Leeuw; Daniel A Duprez; Robert H Fagard; Peter J Gheeraert; Luc H Missault; Jacob J Braun; Roland O Six; Patricia Van Der Niepen; Eoin O'Brien
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

3.  Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension.

Authors:  William B White; Thomas W Littlejohn; Claudio R Majul; Willie Oigman; Rafael Olvera; Mary Seeber; Helmut Schumacher; Giuseppe Mancia
Journal:  Blood Press Monit       Date:  2010-08       Impact factor: 1.444

4.  Age-related difference in the sleep pressure-lowering effect between an angiotensin II receptor blocker and a calcium channel blocker in Asian hypertensives: the ACS1 Study.

Authors:  Kazuomi Kario; Satoshi Hoshide
Journal:  Hypertension       Date:  2015-02-02       Impact factor: 10.190

5.  Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study.

Authors:  Ji-Young Park; Kyoung-Ah Kim; Pil-Whan Park; Ock-Je Lee; Jong Hyeon Ryu; Geun Hyeog Lee; Mun Choun Ha; Jin Sun Kim; Seoung Woo Kang; Kyung Ryul Lee
Journal:  Clin Ther       Date:  2006-11       Impact factor: 3.393

6.  Amlodipine, enalapril, and dependent leg edema in essential hypertension.

Authors:  R Pedrinelli; G Dell'Omo; E Melillo; M Mariani
Journal:  Hypertension       Date:  2000-02       Impact factor: 10.190

7.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redón; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

8.  European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring.

Authors:  Gianfranco Parati; George Stergiou; Eoin O'Brien; Roland Asmar; Lawrence Beilin; Grzegorz Bilo; Denis Clement; Alejandro de la Sierra; Peter de Leeuw; Eamon Dolan; Robert Fagard; John Graves; Geoffrey A Head; Yutaka Imai; Kazuomi Kario; Empar Lurbe; Jean-Michel Mallion; Giuseppe Mancia; Thomas Mengden; Martin Myers; Gbenga Ogedegbe; Takayoshi Ohkubo; Stefano Omboni; Paolo Palatini; Josep Redon; Luis M Ruilope; Andrew Shennan; Jan A Staessen; Gert vanMontfrans; Paolo Verdecchia; Bernard Waeber; Jiguang Wang; Alberto Zanchetti; Yuqing Zhang
Journal:  J Hypertens       Date:  2014-07       Impact factor: 4.844

9.  Results of treatment with telmisartan-amlodipine in hypertensive patients.

Authors:  Thomas W Littlejohn; Claudio R Majul; Rafael Olvera; Mary Seeber; Maureen Kobe; Robert Guthrie; Wille Oigman
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-04       Impact factor: 3.738

Review 10.  Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.

Authors:  Ji-Guang Wang; Eduardo Pimenta; Frank Chwallek
Journal:  Vasc Health Risk Manag       Date:  2014-04-05
View more
  7 in total

1.  A randomized multicenter study on ambulatory blood pressure and arterial stiffness in patients treated with valsartan/amlodipine or nifedipine GITS.

Authors:  Shao-Kun Xu; Qi-Fang Huang; Wei-Fang Zeng; Chang-Sheng Sheng; Yan Li; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-24       Impact factor: 3.738

2.  A randomized controlled trial on the blood pressure-lowering effect of amlodipine and nifedipine-GITS in sustained hypertension.

Authors:  Qi-Fang Huang; Chang-Sheng Sheng; Yan Li; Yu Dou; Mei-Sheng Zheng; Zhi-Ming Zhu; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-04-11       Impact factor: 3.738

3.  What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?

Authors:  Ji-Guang Wang; Yook-Chin Chia; Chen-Huan Chen; Sungha Park; Satoshi Hoshide; Naoko Tomitani; Tomoyuki Kabutoya; Jinho Shin; Yuda Turana; Arieska Ann Soenarta; Jam Chin Tay; Peera Buranakitjaroen; Jennifer Nailes; Huynh Van Minh; Saulat Siddique; Jorge Sison; Guru Prasad Sogunuru; Apichard Sukonthasarn; Boon Wee Teo; Narsingh Verma; Yu-Qing Zhang; Tzung-Dau Wang; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-19       Impact factor: 3.738

Review 4.  S-Amlodipine: An Isomer with Difference-Time to Shift from Racemic Amlodipine.

Authors:  Jamshed Dalal; J C Mohan; S S Iyengar; Jagdish Hiremath; Immaneni Sathyamurthy; Sandeep Bansal; Dhiman Kahali; Arup Dasbiswas
Journal:  Int J Hypertens       Date:  2018-05-20       Impact factor: 2.420

5.  Ambulatory blood pressure response to S-amlodipine in Korean adult patients with uncontrolled essential hypertension: A prospective, observational study.

Authors:  Dong Kyun Kim; Joon Ho Ahn; Ki Hong Lee; Si-Hyuck Kang; Sung Soo Kim; Jin Oh Na; Sang Don Park; Kye Taek Ahn; Jung-Hee Lee; In Hyun Jung; Jongkwon Seo; Woong Gil Choi
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-02-21       Impact factor: 3.738

6.  Efficacy and tolerability of initial high vs low doses of S-(-)-amlodipine in hypertension.

Authors:  Qi Chen; Qi-Fang Huang; Yuan-Yuan Kang; Shao-Kun Xu; Chang-Yuan Liu; Yan Li; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-30       Impact factor: 3.738

7.  Efficacy and Safety of S-Amlodipine 2.5 and 5 mg/d in Hypertensive Patients Who Were Treatment-Naive or Previously Received Antihypertensive Monotherapy.

Authors:  Selçuk Şen; Meral Demir; Zerrin Yiğit; Ali Yağız Üresin
Journal:  J Cardiovasc Pharmacol Ther       Date:  2018-04-12       Impact factor: 2.457

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.